The seminal LoDoCo (Low Dose Colchicine trial) and COLCOT (Colchicine Cardiovascular Outcomes Trial) trials found that low-dose colchicine significantly reduces the risk of cardiovascular death not only in the setting of stable coronary artery disease (CAD) but also in acute coronary syndromes [4,5]; indeed, colchicine suppresses the activation of inflammasome NLRP3 in neutrophils and macrophages by inhibiting tubulin polymerization and microtubule generation. The gene discussed is NLRP3; the disease is coronary artery disorder.